<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02422654</url>
  </required_header>
  <id_info>
    <org_study_id>ACC14373</org_study_id>
    <secondary_id>U1111-1168-5133</secondary_id>
    <nct_id>NCT02422654</nct_id>
  </id_info>
  <brief_title>Taste Evaluation of Different Liquid Formulations With Eliglustat</brief_title>
  <official_title>A Single-blind, Randomized, Unbalanced Crossover Design With 5 Vehicles, 5 Periods, and 5 Sequences, Repeated-doses (With no Ingestion) Study to Assess the Palatability of Eliglustat Prototype Liquid Formulations in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      The purpose of this study is to assess the palatability of eliglustat prototype liquid
      formulations in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration of the study for each subject will be approximately 5 weeks (screening
      period from Day -28 to Day -2, treatment period of 3 days, and follow-up call on Day 5).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of palatability by 100 mm visual analogue scale (VAS) for overall acceptability</measure>
    <time_frame>Each day for 3 days immediately post expectorating the sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of palatability by 100 mm visual analogue scale (VAS) for overall acceptability</measure>
    <time_frame>Each day for 3 days 5 minutes post expectorating the sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of palatability by 100 mm visual analogue scale (VAS) for overall acceptability</measure>
    <time_frame>Each day for 3 days 15 minutes post expectorating the sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of palatability by 100 mm visual analogue scale (VAS) for overall acceptability</measure>
    <time_frame>Each day for 3 days 30 minutes post expectorating the sample</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject's taste preference questionnaire from most preferred to least preferred of the 5 different liquid formulations</measure>
    <time_frame>up to 3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>Concentration 1 eliglustat in vehicle A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concentration 1 eliglustat in vehicle B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concentration 1 eliglustat in vehicle C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concentration 1 eliglustat in vehicle D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concentration 1 eliglustat in vehicle E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concentration 2 eliglustat in vehicle A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concentration 2 eliglustat in vehicle B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concentration 2 eliglustat in vehicle C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concentration 2 eliglustat in vehicle D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concentration 2 eliglustat in vehicle E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concentration 3 eliglustat in vehicle A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concentration 3 eliglustat in vehicle B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concentration 3 eliglustat in vehicle C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concentration 3 eliglustat in vehicle D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concentration 3 eliglustat in vehicle E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eliglustat</intervention_name>
    <description>Pharmaceutical form:liquid formulation
Route of administration: oral without ingestion</description>
    <arm_group_label>Concentration 3 eliglustat in vehicle A</arm_group_label>
    <arm_group_label>Concentration 2 eliglustat in vehicle E</arm_group_label>
    <arm_group_label>Concentration 1 eliglustat in vehicle E</arm_group_label>
    <arm_group_label>Concentration 3 eliglustat in vehicle B</arm_group_label>
    <arm_group_label>Concentration 1 eliglustat in vehicle C</arm_group_label>
    <arm_group_label>Concentration 3 eliglustat in vehicle D</arm_group_label>
    <arm_group_label>Concentration 1 eliglustat in vehicle D</arm_group_label>
    <arm_group_label>Concentration 1 eliglustat in vehicle B</arm_group_label>
    <arm_group_label>Concentration 2 eliglustat in vehicle D</arm_group_label>
    <arm_group_label>Concentration 1 eliglustat in vehicle A</arm_group_label>
    <arm_group_label>Concentration 3 eliglustat in vehicle E</arm_group_label>
    <arm_group_label>Concentration 2 eliglustat in vehicle A</arm_group_label>
    <arm_group_label>Concentration 3 eliglustat in vehicle C</arm_group_label>
    <arm_group_label>Concentration 2 eliglustat in vehicle C</arm_group_label>
    <arm_group_label>Concentration 2 eliglustat in vehicle B</arm_group_label>
    <other_name>GZ385660</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Healthy male and female subjects, 18 to 55 years of age, inclusive.

          -  Normal smell and taste ability to discriminate odor and flavor differences.

        Exclusion criteria:

          -  Poor metabolizer phenotype status for CYP2D6 (predicted based on genotype).

          -  Subject who has smoked within 3 months of inclusion.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>April 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2015</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eliglustat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

